LGND Ligand Pharmaceuticals Inc

Price (delayed)

$123.63

Market cap

$2.06B

P/E Ratio

51.09

Dividend/share

N/A

EPS

$2.42

Enterprise value

$2.39B

Highlights
Ligand Pharmaceuticals's net income has soared by 164% YoY
The revenue has surged by 90% year-on-year and by 12% since the previous quarter
Ligand Pharmaceuticals's quick ratio has shrunk by 90% YoY and by 12% QoQ
Ligand Pharmaceuticals's gross margin has decreased by 6% YoY

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
16.65M
Market cap
$2.06B
Enterprise value
$2.39B
Valuations
Price to earnings (P/E)
51.09
Price to book (P/B)
2.75
Price to sales (P/S)
9.75
EV/EBIT
47.53
EV/EBITDA
28.14
EV/Sales
11.48
Earnings
Revenue
$208.41M
EBIT
$50.34M
EBITDA
$85.02M
Free cash flow
$45.32M
Per share
EPS
$2.42
Free cash flow per share
$2.76
Book value per share
$44.9
Revenue per share
$12.68
TBVPS
$31.05
Balance sheet
Total assets
$1.3B
Total liabilities
$549.28M
Debt
$366M
Equity
$745.84M
Working capital
$341.62M
Liquidity
Debt to equity
0.49
Current ratio
4.57
Quick ratio
4.11
Net debt/EBITDA
3.93
Margins
EBITDA margin
40.8%
Gross margin
83.7%
Net margin
18.8%
Operating margin
12.8%
Efficiency
Return on assets
3.1%
Return on equity
5.5%
Return on invested capital
5.4%
Return on capital employed
4.2%
Return on sales
24.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
2.32%
1 week
7.14%
1 month
-5.29%
1 year
11.81%
YTD
24.31%
QTD
-18.9%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$208.41M
Gross profit
$174.52M
Operating income
$26.77M
Net income
$39.25M
Gross margin
83.7%
Net margin
18.8%
Ligand Pharmaceuticals's operating margin has surged by 190% YoY but it has decreased by 8% QoQ
Ligand Pharmaceuticals's net income has soared by 164% YoY
The net margin has soared by 134% YoY
The revenue has surged by 90% year-on-year and by 12% since the previous quarter

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
51.09
P/B
2.75
P/S
9.75
EV/EBIT
47.53
EV/EBITDA
28.14
EV/Sales
11.48
LGND's P/B is 43% lower than its 5-year quarterly average of 4.8 but 6% higher than its last 4 quarters average of 2.6
The equity has grown by 13% year-on-year and by 5% since the previous quarter
The revenue has surged by 90% year-on-year and by 12% since the previous quarter
The price to sales (P/S) is 43% lower than the 5-year quarterly average of 17.0 and 14% lower than the last 4 quarters average of 11.4

Efficiency

How efficient is Ligand Pharmaceuticals business performance
The ROA has soared by 176% YoY
The company's return on equity has surged by 174% YoY
Ligand Pharmaceuticals's return on sales has surged by 166% QoQ and by 165% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 136% higher than its total liabilities
Ligand Pharmaceuticals's quick ratio has shrunk by 90% YoY and by 12% QoQ
LGND's current ratio has dropped by 89% year-on-year and by 9% since the previous quarter
The debt is 51% less than the equity
The debt to equity has contracted by 29% YoY and by 23% from the previous quarter
The debt has contracted by 20% from the previous quarter and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.